APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lipid-lowering Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Lipid-lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchLipid-lowering Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Lipid-lowering Drugs Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Lipid-lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lipid-lowering Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Lipid-lowering Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Lipid-lowering Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Lipid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lipid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lipid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Lipid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lipid-lowering Drugs include Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Amgen Inc. and AbbVie, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lipid-lowering Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lipid-lowering Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lipid-lowering Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lipid-lowering Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Lipid-lowering Drugs Segment by Company

Takeda Pharmaceutical Company Limited

Sun Pharmaceutical Industries Ltd.

Sanofi

Novartis AG

Merck & Co., Inc.

Pfizer, Inc.

GlaxoSmithKline plc

Amgen Inc.

AbbVie, Inc.

AstraZeneca PLC

Viatris (Mylan N.V.)

Dr. Reddy’s Laboratories Ltd.

Lipid-lowering Drugs Segment by Type

Statins & Combination

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibrates

PCSK9 Inhibitors

Others

Lipid-lowering Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Lipid-lowering Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lipid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid-lowering Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lipid-lowering Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lipid-lowering Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Lipid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Lipid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Lipid-lowering Drugs Industry Trends Table 2. Lipid-lowering Drugs Industry Drivers Table 3. Lipid-lowering Drugs Industry Opportunities and Challenges Table 4. Lipid-lowering Drugs Industry Restraints Table 5. Global Lipid-lowering Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Lipid-lowering Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Lipid-lowering Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Lipid-lowering Drugs Sales Market Share by Manufacturers Table 9. Global Lipid-lowering Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Lipid-lowering Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Lipid-lowering Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Lipid-lowering Drugs Manufacturers, Product Type & Application Table 13. Global Lipid-lowering Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Lipid-lowering Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Statins & Combination Table 17. Major Manufacturers of Bile Acid Sequestrants Table 18. Major Manufacturers of Cholesterol Absorption Inhibitors Table 19. Major Manufacturers of Fibrates Table 20. Major Manufacturers of PCSK9 Inhibitors Table 21. Major Manufacturers of Others Table 22. Global Lipid-lowering Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Lipid-lowering Drugs Sales by Type (2021-2026) & (k units) Table 24. Global Lipid-lowering Drugs Sales by Type (2027-2032) & (k units) Table 25. Global Lipid-lowering Drugs Sales Market Share by Type (2021-2026) Table 26. Global Lipid-lowering Drugs Sales Market Share by Type (2027-2032) Table 27. Global Lipid-lowering Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Lipid-lowering Drugs Revenue by Type (2021-2026) & (k units) Table 29. Global Lipid-lowering Drugs Revenue by Type (2027-2032) & (k units) Table 30. Global Lipid-lowering Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Lipid-lowering Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Pharmacies Table 33. Major Manufacturers of Online Pharmacies Table 34. Major Manufacturers of Retail Pharmacies Table 35. Global Lipid-lowering Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Lipid-lowering Drugs Sales by Application (2021-2026) & (k units) Table 37. Global Lipid-lowering Drugs Sales by Application (2027-2032) & (k units) Table 38. Global Lipid-lowering Drugs Sales Market Share by Application (2021-2026) Table 39. Global Lipid-lowering Drugs Sales Market Share by Application (2027-2032) Table 40. Global Lipid-lowering Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Lipid-lowering Drugs Revenue by Application (2021-2026) & (k units) Table 42. Global Lipid-lowering Drugs Revenue by Application (2027-2032) & (k units) Table 43. Global Lipid-lowering Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Lipid-lowering Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Lipid-lowering Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Lipid-lowering Drugs Sales by Region (2021-2026) & (k units) Table 47. Global Lipid-lowering Drugs Sales Market Share by Region (2021-2026) Table 48. Global Lipid-lowering Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Lipid-lowering Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Lipid-lowering Drugs Sales by Country (2021-2026) & (k units) Table 52. North America Lipid-lowering Drugs Sales by Country (2027-2032) & (k units) Table 53. Europe Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Lipid-lowering Drugs Sales by Country (2021-2026) & (k units) Table 55. Europe Lipid-lowering Drugs Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Lipid-lowering Drugs Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Lipid-lowering Drugs Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Lipid-lowering Drugs Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Lipid-lowering Drugs Sales by Country (2027-2032) & (k units) Table 62. Global Lipid-lowering Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Lipid-lowering Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Lipid-lowering Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Lipid-lowering Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Lipid-lowering Drugs Revenue Market Share by Region (2027-2032) Table 67. Takeda Pharmaceutical Company Limited Company Information Table 68. Takeda Pharmaceutical Company Limited Business Overview Table 69. Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolio Table 71. Takeda Pharmaceutical Company Limited Recent Development Table 72. Sun Pharmaceutical Industries Ltd. Company Information Table 73. Sun Pharmaceutical Industries Ltd. Business Overview Table 74. Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolio Table 76. Sun Pharmaceutical Industries Ltd. Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Sanofi Lipid-lowering Drugs Product Portfolio Table 81. Sanofi Recent Development Table 82. Novartis AG Company Information Table 83. Novartis AG Business Overview Table 84. Novartis AG Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novartis AG Lipid-lowering Drugs Product Portfolio Table 86. Novartis AG Recent Development Table 87. Merck & Co., Inc. Company Information Table 88. Merck & Co., Inc. Business Overview Table 89. Merck & Co., Inc. Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Merck & Co., Inc. Lipid-lowering Drugs Product Portfolio Table 91. Merck & Co., Inc. Recent Development Table 92. Pfizer, Inc. Company Information Table 93. Pfizer, Inc. Business Overview Table 94. Pfizer, Inc. Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Pfizer, Inc. Lipid-lowering Drugs Product Portfolio Table 96. Pfizer, Inc. Recent Development Table 97. GlaxoSmithKline plc Company Information Table 98. GlaxoSmithKline plc Business Overview Table 99. GlaxoSmithKline plc Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolio Table 101. GlaxoSmithKline plc Recent Development Table 102. Amgen Inc. Company Information Table 103. Amgen Inc. Business Overview Table 104. Amgen Inc. Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Amgen Inc. Lipid-lowering Drugs Product Portfolio Table 106. Amgen Inc. Recent Development Table 107. AbbVie, Inc. Company Information Table 108. AbbVie, Inc. Business Overview Table 109. AbbVie, Inc. Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. AbbVie, Inc. Lipid-lowering Drugs Product Portfolio Table 111. AbbVie, Inc. Recent Development Table 112. AstraZeneca PLC Company Information Table 113. AstraZeneca PLC Business Overview Table 114. AstraZeneca PLC Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. AstraZeneca PLC Lipid-lowering Drugs Product Portfolio Table 116. AstraZeneca PLC Recent Development Table 117. Viatris (Mylan N.V.) Company Information Table 118. Viatris (Mylan N.V.) Business Overview Table 119. Viatris (Mylan N.V.) Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolio Table 121. Viatris (Mylan N.V.) Recent Development Table 122. Dr. Reddy’s Laboratories Ltd. Company Information Table 123. Dr. Reddy’s Laboratories Ltd. Business Overview Table 124. Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolio Table 126. Dr. Reddy’s Laboratories Ltd. Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Lipid-lowering Drugs Distributors List Table 130. Lipid-lowering Drugs Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Lipid-lowering Drugs Product Image Figure 2. Global Lipid-lowering Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lipid-lowering Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Lipid-lowering Drugs Sales (2021-2032) & (k units) Figure 5. Global Lipid-lowering Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Lipid-lowering Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Statins & Combination Image Figure 9. Bile Acid Sequestrants Image Figure 10. Cholesterol Absorption Inhibitors Image Figure 11. Fibrates Image Figure 12. PCSK9 Inhibitors Image Figure 13. Others Image Figure 14. Global Lipid-lowering Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Lipid-lowering Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Lipid-lowering Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Lipid-lowering Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Lipid-lowering Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Lipid-lowering Drugs Revenue Market Share by Type (2021-2032) Figure 20. Hospital Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Retail Pharmacies Image Figure 23. Global Lipid-lowering Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Lipid-lowering Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Lipid-lowering Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Lipid-lowering Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Lipid-lowering Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Lipid-lowering Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Lipid-lowering Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Lipid-lowering Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Lipid-lowering Drugs Sales Market Share by Country (2021-2032) Figure 43. China Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Lipid-lowering Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Lipid-lowering Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Lipid-lowering Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Lipid-lowering Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Lipid-lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Lipid-lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Lipid-lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Lipid-lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Lipid-lowering Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Lipid-lowering Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Statins & Combination
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibrates
  • PCSK9 Inhibitors
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Amgen Inc.
  • AbbVie, Inc.
  • AstraZeneca PLC
  • Viatris (Mylan N.V.)
  • Dr. Reddy’s Laboratories Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lipid-lowering Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lipid-lowering Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Lipid-lowering Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Lipid-lowering Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Lipid-lowering Drugs Market Dynamics
  1. 2.1 Lipid-lowering Drugs Industry Trends
  2. 2.2 Lipid-lowering Drugs Industry Drivers
  3. 2.3 Lipid-lowering Drugs Industry Opportunities and Challenges
  4. 2.4 Lipid-lowering Drugs Industry Restraints
3 Lipid-lowering Drugs Market by Manufacturers
  1. 3.1 Global Lipid-lowering Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Lipid-lowering Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Lipid-lowering Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Lipid-lowering Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lipid-lowering Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Lipid-lowering Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Lipid-lowering Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lipid-lowering Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lipid-lowering Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lipid-lowering Drugs Tier 1, Tier 2, and Tier 3
4 Lipid-lowering Drugs Market by Type
  1. 4.1 Lipid-lowering Drugs Type Introduction
  2. 4.1.1 Statins & Combination
  3. 4.1.2 Bile Acid Sequestrants
  4. 4.1.3 Cholesterol Absorption Inhibitors
  5. 4.1.4 Fibrates
  6. 4.1.5 PCSK9 Inhibitors
  7. 4.1.6 Others
  8. 4.2 Global Lipid-lowering Drugs Sales by Type
  9. 4.2.1 Global Lipid-lowering Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Lipid-lowering Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Lipid-lowering Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Lipid-lowering Drugs Revenue by Type
  13. 4.3.1 Global Lipid-lowering Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Lipid-lowering Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Lipid-lowering Drugs Revenue Market Share by Type (2021-2032)
5 Lipid-lowering Drugs Market by Application
  1. 5.1 Lipid-lowering Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Lipid-lowering Drugs Sales by Application
  6. 5.2.1 Global Lipid-lowering Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Lipid-lowering Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Lipid-lowering Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Lipid-lowering Drugs Revenue by Application
  10. 5.3.1 Global Lipid-lowering Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Lipid-lowering Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Lipid-lowering Drugs Revenue Market Share by Application (2021-2032)
6 Global Lipid-lowering Drugs Sales by Region
  1. 6.1 Global Lipid-lowering Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lipid-lowering Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Lipid-lowering Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Lipid-lowering Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Lipid-lowering Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Lipid-lowering Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Lipid-lowering Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Lipid-lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Lipid-lowering Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Lipid-lowering Drugs Revenue by Region
  1. 7.1 Global Lipid-lowering Drugs Revenue by Region
  2. 7.1.1 Global Lipid-lowering Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Lipid-lowering Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Lipid-lowering Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Lipid-lowering Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Lipid-lowering Drugs Revenue (2021-2032)
  8. 7.2.2 North America Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Lipid-lowering Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Lipid-lowering Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Lipid-lowering Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Lipid-lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 Sun Pharmaceutical Industries Ltd.
  8. 8.2.1 Sun Pharmaceutical Industries Ltd. Company Information
  9. 8.2.2 Sun Pharmaceutical Industries Ltd. Business Overview
  10. 8.2.3 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Lipid-lowering Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Lipid-lowering Drugs Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Merck & Co., Inc.
  26. 8.5.1 Merck & Co., Inc. Company Information
  27. 8.5.2 Merck & Co., Inc. Business Overview
  28. 8.5.3 Merck & Co., Inc. Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co., Inc. Lipid-lowering Drugs Product Portfolio
  30. 8.5.5 Merck & Co., Inc. Recent Developments
  31. 8.6 Pfizer, Inc.
  32. 8.6.1 Pfizer, Inc. Company Information
  33. 8.6.2 Pfizer, Inc. Business Overview
  34. 8.6.3 Pfizer, Inc. Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer, Inc. Lipid-lowering Drugs Product Portfolio
  36. 8.6.5 Pfizer, Inc. Recent Developments
  37. 8.7 GlaxoSmithKline plc
  38. 8.7.1 GlaxoSmithKline plc Company Information
  39. 8.7.2 GlaxoSmithKline plc Business Overview
  40. 8.7.3 GlaxoSmithKline plc Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline plc Recent Developments
  43. 8.8 Amgen Inc.
  44. 8.8.1 Amgen Inc. Company Information
  45. 8.8.2 Amgen Inc. Business Overview
  46. 8.8.3 Amgen Inc. Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Inc. Lipid-lowering Drugs Product Portfolio
  48. 8.8.5 Amgen Inc. Recent Developments
  49. 8.9 AbbVie, Inc.
  50. 8.9.1 AbbVie, Inc. Company Information
  51. 8.9.2 AbbVie, Inc. Business Overview
  52. 8.9.3 AbbVie, Inc. Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie, Inc. Lipid-lowering Drugs Product Portfolio
  54. 8.9.5 AbbVie, Inc. Recent Developments
  55. 8.10 AstraZeneca PLC
  56. 8.10.1 AstraZeneca PLC Company Information
  57. 8.10.2 AstraZeneca PLC Business Overview
  58. 8.10.3 AstraZeneca PLC Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca PLC Lipid-lowering Drugs Product Portfolio
  60. 8.10.5 AstraZeneca PLC Recent Developments
  61. 8.11 Viatris (Mylan N.V.)
  62. 8.11.1 Viatris (Mylan N.V.) Company Information
  63. 8.11.2 Viatris (Mylan N.V.) Business Overview
  64. 8.11.3 Viatris (Mylan N.V.) Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolio
  66. 8.11.5 Viatris (Mylan N.V.) Recent Developments
  67. 8.12 Dr. Reddy’s Laboratories Ltd.
  68. 8.12.1 Dr. Reddy’s Laboratories Ltd. Company Information
  69. 8.12.2 Dr. Reddy’s Laboratories Ltd. Business Overview
  70. 8.12.3 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolio
  72. 8.12.5 Dr. Reddy’s Laboratories Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lipid-lowering Drugs Value Chain Analysis
  2. 9.1.1 Lipid-lowering Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lipid-lowering Drugs Production Mode & Process
  6. 9.2 Lipid-lowering Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lipid-lowering Drugs Distributors
  9. 9.2.3 Lipid-lowering Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst